Summary
19X Chart
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and Symbravo remains uncertain.
Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings
The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Axsome Therapeutics, Inc. (19X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Axsome Therapeutics, Inc. ever had a stock split?
Axsome Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Herriot Tabuteau CEO | XDUS Exchange | US05464T1043 ISIN |
| US Country | 712 Employees | - Last Dividend | - Last Split | 19 Nov 2015 IPO Date |
Overview
Axsome Therapeutics, Inc. is a forward-thinking biopharmaceutical entity dedicated to the innovation of novel treatments geared towards addressing the complexities of central nervous system (CNS) disorders. Rooted in the quest to improve patient care within the United States, Axsome stands out for its dynamic approach towards tackling conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, Alzheimer's disease agitation, and more. The foundation of the company's operations, established in 2012 and headquartered in New York, New York, underscores a commitment to pushing the boundaries of medical science, particularly in the CNS domain. Through its research collaboration with Duke University focused on smoking cessation, Axsome exemplifies its dedication to pioneering efforts in enhancing therapeutic outcomes.
Products and Services
- Auvelity (dextromethorphan-bupropion): An innovative N-methyl-D-aspartate receptor antagonist showcasing multimodal activity, specifically indicated for the treatment of major depressive disorder, highlighting Axsome's focus on addressing mental health challenges with novel approaches.
- Sunosi (solriamfetol): A targeted medication addressing excessive daytime sleepiness in patients battling narcolepsy or obstructive sleep apnea, underlining the company's dedication to improving quality of life for individuals with sleep disorders.
Under Development:
- AXS-05: Currently in Phase III clinical trial for Alzheimer's disease agitation, showcasing Axsome's deep dive into neurodegenerative disease management. Additionally, it demonstrates versatility with its completion of Phase II clinical trial for smoking cessation.
- AXS-07: An investigational medicine that has successfully completed Phase III trials, crafted for the acute treatment of migraine, providing a glimpse into Axsome's commitment to tackling severe headache disorders.
- AXS-12: In Phase III trial to treat narcolepsy, positioning Axsome at the forefront of addressing sleep disorders with cutting-edge solutions.
- AXS-14: Having completed Phase III trial for the treatment of fibromyalgia, this selective and potent norepinephrine reuptake inhibitor represents Axsome's venture into pain management and other potential conditions.
- Solriamfetol: Beyond its approved use, it is under investigation in a Phase 2 trial for addressing attention-deficit/hyperactivity disorder. Additionally, its exploration extends to major depressive, binge eating, and shift work disorders, showing Axsome's holistic approach to CNS conditions.
